Identification of pathways involved in paclitaxel activity in cervical cancer.

Paclitaxel is one of the key chemotherapeutic drugs widely used to treat various types of cancer. Many cervical cancer patients exhibit selectivity in response to thereapy, however, which is considered to be correlated with drug-gene-pathways. The aim of this study was to identify pathways involved in paclitaxel activity in cervical cancer. Gene expression data was obtained from the NCBI Gene Expression Omnibus and the associations between paclitaxel and genes from DrugBank, MATADOR, TTD, CTD and SuperTarget databases. Differentially expressed genes in cervical cancer were identified using the significance analysis of microarrays (SAM) statistical technique. Pathway analysis was performed according to the Kyoto Encyclopedia of Genes and Genomes (KEGG) database using the software package SubpathwayMiner to predict target genes of paclitaxel in cervical cancer and regulated pathways. We found that paclitaxel, which exhibits anticancer activity in cervical cancer, may interact with these differentially expressed genes and their corresponding signaling pathways. Our study presents the first in-depth, large-scale analysis of pathways involved in paclitaxel activity in cervical cancer. Interestingly, these pathways have not been reported to be involved in other tumors. Thus our findings may contribute to the understanding of the mechanisms underlying paclitaxel resistance in cervical cancer.

[1]  T. Hogberg.  Chemotherapy: Current drugs still have potential in advanced ovarian cancer , 2010, Nature Reviews Clinical Oncology.

[2]  I. Kawase,et al.  A Phase II Study Directed by a Clinical Pathway for Carboplatin and Weekly Paclitaxel in Previously Untreated Patients with Unresectable Non-Small Cell Lung Cancer , 2010, Chemotherapy.

[3]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[4]  T. Rajkumar,et al.  A 7 gene expression score predicts for radiation response in cancer cervix , 2009, BMC Cancer.

[5]  H. Hollema,et al.  The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer , 2008, British Journal of Cancer.

[6]  H. Yoshikawa,et al.  A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). , 2010, Japanese journal of clinical oncology.

[7]  Kiyoko F. Aoki-Kinoshita,et al.  From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..

[8]  Marrije R Buist,et al.  Gene expression in early stage cervical cancer. , 2008, Gynecologic oncology.

[9]  B. Groner,et al.  Peptide Aptamers with Binding Specificity for the Intracellular Domain of the ErbB2 Receptor Interfere with AKT Signaling and Sensitize Breast Cancer Cells to Taxol , 2006, Molecular Cancer Research.

[10]  P. Tan,et al.  Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. , 2010, American journal of clinical pathology.

[11]  Andrew D Sharrocks,et al.  Transcriptional regulation by the MAP kinase signaling cascades. , 2003, Gene.

[12]  Chunquan Li,et al.  SubpathwayMiner: a software package for flexible identification of pathways , 2009, Nucleic acids research.

[13]  H. Gogas,et al.  Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group. , 2010, Clinical breast cancer.

[14]  M. Wolfson,et al.  The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. , 2001, Experimental cell research.

[15]  A. Levine,et al.  The coordinate regulation of the p53 and mTOR pathways in cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K. M. Nicholson,et al.  The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.

[17]  Y. Yarden,et al.  Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. , 1987, Biochemistry.

[18]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[19]  D. Park,et al.  Neoadjuvant Paclitaxel and Cisplatin in Uterine Cervical Cancer: Long-Term Results , 2009, International Journal of Gynecologic Cancer.

[20]  A. Kemona,et al.  Helicobacter pylori infection and expressions of EGF, EGFR and c-erbB-2 proteins in gastric carcinoma. , 2010, Folia histochemica et cytobiologica.

[21]  A. Levine,et al.  The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. , 2007, Cancer research.

[22]  Y. Bang,et al.  Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer , 2010, Journal of Korean medical science.

[23]  M. Waterfield,et al.  Epidermal growth factor binding induces a conformational change in the external domain of its receptor. , 1989, The EMBO journal.

[24]  N. Abdel Wahab,et al.  Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation , 2009, Medical oncology.

[25]  M. Mansukhani,et al.  Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: Potential role in progression , 2008, Genes, chromosomes & cancer.

[26]  G. de Rosa,et al.  Role of Polysomy 17 in Transitional Cell Carcinoma of the Bladder: Immunohistochemical Study of HER2/neu Expression and FISH Analysis of c-erbB-2 Gene and Chromosome 17 , 2009, International journal of surgical pathology.